TIM3 as a therapeutic target in anaplastic thyroid cancer: upregulation in M2-like macrophages induced by tumor microenvironment-derived TGFβ1

IF 5.4 2区 医学 Q1 ONCOLOGY
The Journal of Pathology Pub Date : 2026-10-04 Epub Date: 2026-08-05 DOI:10.1002/path.70104
Agustina Jaroszewski, Yeon-Sook Choi, Florencia Hellriegel, Wei Zhang, Fernando Carrizo, Dong Eun Song, María Victoria Laborie, Marcelo Ruggieri, Emiliano Peretti, María Victoria Banus, Cinthia Carolina Stempin, Juan Pablo Nicola, Eva Virginia Acosta Rodríguez, Chi-Ping Day, Gabriel Needle, Inés Califano, Constanza Fernanda Ramacciotti, Ramiro Iglesias-Bartolome, Won Gu Kim, Min Ji Jeon, Laura Fozzatti
{"title":"TIM3 as a therapeutic target in anaplastic thyroid cancer: upregulation in M2-like macrophages induced by tumor microenvironment-derived TGFβ1","authors":"Agustina Jaroszewski,&nbsp;Yeon-Sook Choi,&nbsp;Florencia Hellriegel,&nbsp;Wei Zhang,&nbsp;Fernando Carrizo,&nbsp;Dong Eun Song,&nbsp;María Victoria Laborie,&nbsp;Marcelo Ruggieri,&nbsp;Emiliano Peretti,&nbsp;María Victoria Banus,&nbsp;Cinthia Carolina Stempin,&nbsp;Juan Pablo Nicola,&nbsp;Eva Virginia Acosta Rodríguez,&nbsp;Chi-Ping Day,&nbsp;Gabriel Needle,&nbsp;Inés Califano,&nbsp;Constanza Fernanda Ramacciotti,&nbsp;Ramiro Iglesias-Bartolome,&nbsp;Won Gu Kim,&nbsp;Min Ji Jeon,&nbsp;Laura Fozzatti","doi":"10.1002/path.70104","DOIUrl":null,"url":null,"abstract":"<p>Thyroid cancer (TC) is the most common endocrine malignancy. While papillary thyroid cancer (PTC) generally has a favorable prognosis, anaplastic thyroid cancer (ATC) is rare but highly aggressive, with limited treatment options, highlighting the urgent need for novel therapeutic targets. Macrophages are a major component of the immune infiltrate in TC, and their abundance is associated with poor prognosis. We recently identified upregulation of the immune checkpoint TIM3 (T-cell immunoglobulin and mucin-domain containing protein 3) on M2-like macrophages both <i>in vitro</i> and in ATC xenografts. In addition, we have shown that transforming growth factor β1 (TGFβ1) promotes macrophage polarization toward an M2-like phenotype. However, the role and clinical significance of TGFβ1 in regulating TIM3 expression in TC-associated macrophages remains unclear. We found that TGFβ1 secreted by ATC cells significantly increased <i>HAVCR2</i> (TIM3) mRNA expression in human monocytes. Analysis of patient samples demonstrated elevated TIM3 expression in both PTC and ATC tissues compared with adenoma and normal thyroid counterparts. Analysis of publicly available single-cell RNA sequencing datasets further showed increased TIM3 expression in T cells from both tumor types. Notably, TIM3 upregulation was also localized to M2-like macrophages within the thyroid tumor microenvironment (TME), and positively correlated with <i>TGFB1</i>/<i>CD163</i> expression, suggesting the involvement of a TGFβ–TIM3 axis in macrophages in TC. Combined targeting of the TIM3 and PD1 pathway in an immunocompetent mouse model of ATC led to a significant reduction in tumor growth. Together, these findings highlight TIM3 as a promising immunotherapeutic target in TC, with the potential to suppress macrophage-mediated pro-tumor activity while enhancing T-cell-driven anti-tumor immunity within the thyroid TME. © 2026 The Pathological Society of Great Britain and Ireland. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.</p>","PeriodicalId":232,"journal":{"name":"The Journal of Pathology","volume":"270 3","pages":"342-356"},"PeriodicalIF":5.4000,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Pathology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/path.70104","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Thyroid cancer (TC) is the most common endocrine malignancy. While papillary thyroid cancer (PTC) generally has a favorable prognosis, anaplastic thyroid cancer (ATC) is rare but highly aggressive, with limited treatment options, highlighting the urgent need for novel therapeutic targets. Macrophages are a major component of the immune infiltrate in TC, and their abundance is associated with poor prognosis. We recently identified upregulation of the immune checkpoint TIM3 (T-cell immunoglobulin and mucin-domain containing protein 3) on M2-like macrophages both in vitro and in ATC xenografts. In addition, we have shown that transforming growth factor β1 (TGFβ1) promotes macrophage polarization toward an M2-like phenotype. However, the role and clinical significance of TGFβ1 in regulating TIM3 expression in TC-associated macrophages remains unclear. We found that TGFβ1 secreted by ATC cells significantly increased HAVCR2 (TIM3) mRNA expression in human monocytes. Analysis of patient samples demonstrated elevated TIM3 expression in both PTC and ATC tissues compared with adenoma and normal thyroid counterparts. Analysis of publicly available single-cell RNA sequencing datasets further showed increased TIM3 expression in T cells from both tumor types. Notably, TIM3 upregulation was also localized to M2-like macrophages within the thyroid tumor microenvironment (TME), and positively correlated with TGFB1/CD163 expression, suggesting the involvement of a TGFβ–TIM3 axis in macrophages in TC. Combined targeting of the TIM3 and PD1 pathway in an immunocompetent mouse model of ATC led to a significant reduction in tumor growth. Together, these findings highlight TIM3 as a promising immunotherapeutic target in TC, with the potential to suppress macrophage-mediated pro-tumor activity while enhancing T-cell-driven anti-tumor immunity within the thyroid TME. © 2026 The Pathological Society of Great Britain and Ireland. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

TIM3作为间变性甲状腺癌的治疗靶点:肿瘤微环境源性tgf - β1诱导m2样巨噬细胞上调
甲状腺癌是最常见的内分泌恶性肿瘤。虽然甲状腺乳头状癌(PTC)通常具有良好的预后,但间变性甲状腺癌(ATC)罕见但具有高度侵袭性,治疗方案有限,迫切需要新的治疗靶点。巨噬细胞是TC免疫浸润的主要组成部分,巨噬细胞数量多与预后不良有关。我们最近在体外和ATC异种移植物中发现了m2样巨噬细胞免疫检查点TIM3 (t细胞免疫球蛋白和粘蛋白结构域蛋白3)的上调。此外,我们已经证明转化生长因子β1 (tgf - β1)促进巨噬细胞向m2样表型极化。然而,tgf - β1在tc相关巨噬细胞中调节TIM3表达的作用和临床意义尚不清楚。我们发现ATC细胞分泌的tgf - β1显著增加了人单核细胞中HAVCR2 (TIM3) mRNA的表达。患者样本分析显示,与腺瘤和正常甲状腺组织相比,PTC和ATC组织中TIM3表达升高。对公开可用的单细胞RNA测序数据集的分析进一步显示,两种肿瘤类型的T细胞中TIM3表达增加。值得注意的是,TIM3的上调也局限于甲状腺肿瘤微环境(TME)内的m2样巨噬细胞,并与TGFB1/CD163的表达呈正相关,提示TGFβ-TIM3轴参与TC巨噬细胞。在免疫功能小鼠ATC模型中,联合靶向TIM3和PD1通路可显著降低肿瘤生长。总之,这些发现突出了TIM3作为TC中有希望的免疫治疗靶点,具有抑制巨噬细胞介导的促肿瘤活性的潜力,同时增强甲状腺TME中t细胞驱动的抗肿瘤免疫。©2026英国和爱尔兰病理学会。这篇文章是由美国政府雇员贡献的,他们的工作在美国属于公有领域。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
The Journal of Pathology
The Journal of Pathology 医学-病理学
CiteScore
14.10
自引率
1.40%
发文量
144
审稿时长
3-8 weeks
期刊介绍: The Journal of Pathology aims to serve as a translational bridge between basic biomedical science and clinical medicine with particular emphasis on, but not restricted to, tissue based studies. The main interests of the Journal lie in publishing studies that further our understanding the pathophysiological and pathogenetic mechanisms of human disease. The Journal of Pathology welcomes investigative studies on human tissues, in vitro and in vivo experimental studies, and investigations based on animal models with a clear relevance to human disease, including transgenic systems. As well as original research papers, the Journal seeks to provide rapid publication in a variety of other formats, including editorials, review articles, commentaries and perspectives and other features, both contributed and solicited.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书